Welcome to LookChem.com Sign In|Join Free

CAS

  • or

137945-48-3

Post Buying Request

137945-48-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 6H-Dibenzo[b,d]pyran-9-carboxylicacid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-,(6aR,10aR)-

    Cas No: 137945-48-3

  • No Data

  • 1 Gram

  • 10000 Metric Ton/Month

  • Shanghai Upbio Tech Co.,Ltd
  • Contact Supplier

137945-48-3 Usage

General Description

Ajulemic acid, also known as AJA or CT-3, belongs to the family of synthetic cannabinoids developed as an analgesic and anti-inflammatory drug. It exhibits its therapeutic effects without the accompanying psychoactive effects observed in other cannabinoids. The structure of AJA closely resembles the structure of Tetrahydrocannabinol (THC), which is the principal psychoactive constituent of cannabis. However, differences in certain functional groups make Ajulemic acid therapeutically potent without psychoactive properties. Research has shown potential therapeutic applications of AJA in treating conditions like chronic neuropathic pain, inflammation, fibromyalgia, and other neurodegenerative diseases.

Check Digit Verification of cas no

The CAS Registry Mumber 137945-48-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,9,4 and 5 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 137945-48:
(8*1)+(7*3)+(6*7)+(5*9)+(4*4)+(3*5)+(2*4)+(1*8)=163
163 % 10 = 3
So 137945-48-3 is a valid CAS Registry Number.
InChI:InChI=1/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1

137945-48-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid

1.2 Other means of identification

Product number -
Other names DMH-THC-11-OIC

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:137945-48-3 SDS

137945-48-3Relevant articles and documents

Synthetic Nonpsychotropic Cannabinoids with Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities

Burstein, Sumner H.,Audette, Charlene A.,Breuer, Aviva,Devane, William A.,Colodner, Sharona,et al.

, p. 3135 - 3141 (1992)

Two strategies for the design of therapeutically useful cannabinoids have been combined to produce compounds with greatly increased antiinflammatory activity and with a low potential for adverse side effects.Enantiomeric cannabinoids with a carboxylic acid group at position 7 and with an elongated and branched alkyl sidechain at position 5' have been synthesized and tested for antiinflammatory activity.They were effective when given orally at doses of 10 μg/kg in reducing paw edema in mice that had been induced by either arachidonic acid or platelet activating factor.Leukocyte adhesion to culture dishes was also reduced in peritoneal cells from mice in which the cannabinoids were orally administered in the same dose range as for the paw edema tests.Antinociception could be observed in the mouse hot plate assay; however, little stereochemical preference was seen in contrast to the above tests where the 3R,4R compounds are more active than the 3S,4S enantiomers.Finally, in agreement with earlier reports on the naturally occurring pentyl side chain acids, the synthetic acids showed little activity in producing catalepsy in the mouse, suggesting that they would be nonpsychotropic in humans.

METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL

-

Page/Page column 35-36, (2019/05/10)

The invention provides methods and compositions relating to an ultrapure formulation of 5-(1,1-dimethylheptyl)-resorcinol (ultrapure DMHR). The invention features methods for making ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities). The invention also features methods of making cannabinoids, such as (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid (ajulemic acid), using ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities) in the resulting cannabinoid preparation.

ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS

-

Page/Page column title page; 6; figure 1, (2008/06/13)

The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, (3R,4R)-Δ8-THC-11-oic acids, for treating or preventing nausea and relieving symptoms thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 137945-48-3